{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:14:33Z","timestamp":1793304873498,"version":"4.5.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Older patients with classical Hodgkin lymphoma (cHL) require more effective and less toxic therapies than younger patients. In this multicenter, prospective, phase 2 study, we\u00a0investigated a new firstline therapy regimen comprising 6 cycles of prednisone (40\u00a0mg\/m2, days 1-5), vinblastine (6 mg\/m2, day 1), doxorubicin (40 mg\/m2, day 1), and bendamustine (120 mg\/m2, day 1) (PVAB regimen) every 21 days for patients with newly diagnosed cHL aged \u226561 years with an advanced Ann Arbor stage. A Mini Nutritional Assessment score \u226517 was the cutoff value for patients aged \u226570 years. The primary end point was the complete metabolic response (CMR) rate after 6 cycles. The median age of the 89 included patients was 68 years (range, 61-88 years), with 35 patients (39%) aged \u226570 years. Seventy-eight patients (88%) completed the 6 cycles. The toxicity rate was acceptable, with a 20% rate of related serious adverse events. CMR was achieved by 69 patients (77.5%; 95% confidence interval [CI], 67-86). After a median follow-up of 42 months, 31 patients progressed or relapsed (35%), and 24 died (27%) from HL (n\u00a0= 11), toxicity during treatment (n\u00a0= 4), secondary cancers (n\u00a0= 6), or other causes (n\u00a0= 3). The 4-year progression-free survival (PFS) and overall survival rates were 50% and 69%, respectively. Multivariate analysis showed that liver involvement (P\u00a0= .001), lymphopenia (P\u00a0= .001), CRP (P\u00a0= .0005), and comedications (P\u00a0= .003) were independently associated with PFS. The PVAB regimen yielded a high CMR rate with acceptable toxicity. Over long-term follow-up, survival end points were influenced by unrelated lymphoma events. This trial was registered at www.clinicaltrials.gov as #NCT02414568 and at EudraCT as 2014-001002-17.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023021564","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T16:20:50Z","timestamp":1700324450000},"page":"983-995","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-3718","authenticated-orcid":false,"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"first","affiliation":[{"name":"1Department of Hematology, Hopital Lyon Sud, Claude Bernard Lyon 1 University, Pierre Benite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7059-5917","authenticated-orcid":false,"given":"Daphn\u00e9","family":"Krzisch","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Centre Leon Berard, Claude Bernard Lyon 1 University, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8592-3773","authenticated-orcid":false,"given":"Salim","family":"Kanoun","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Cancer Research Center of Toulouse, Team 9, INSERM Unit\u00e9 Mixte de Recherche 1037, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Claire","family":"Gac","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Institut d'Hematologie de Basse Normandie, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Guidez","sequence":"additional","affiliation":[{"name":"6Hematology Department, Centre Hospitalier Universitaire, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Touati","sequence":"additional","affiliation":[{"name":"7Department of Hematology, H\u00f4pital Dupuytren, Centre Hospitalier Universitaire, Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Laribi","sequence":"additional","affiliation":[{"name":"8Hematology Department, Centre Hospitalier, Le Mans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Centre Hospitalier Universitaire Lille, Universite de Lille, ULR 7365 Groupe de Recherche sur les formes Injectables et les Technologies Associ\u00e9es, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Bonnet","sequence":"additional","affiliation":[{"name":"10Department of Hematology, University Hospital Liege, Liege, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Waultier-Rascalou","sequence":"additional","affiliation":[{"name":"11Hematology of Department, Centre Hospitalier Universitaire, Nimes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Orsini-Piocelle","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Centre Hospitalier Universitaire, Universit\u00e9 Catholique de Louvain Namur, Universit\u00e9 Catholique de Louvain, Yvoir, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Fournier","sequence":"additional","affiliation":[{"name":"14Department of Statistics, Lymphoma Study Association Clinical Research, Hopital Lyon Sud, Pierre Benite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Morand","sequence":"additional","affiliation":[{"name":"14Department of Statistics, Lymphoma Study Association Clinical Research, Hopital Lyon Sud, Pierre Benite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0771-7824","authenticated-orcid":false,"given":"Alina","family":"Berriolo-Riedinger","sequence":"additional","affiliation":[{"name":"15Department of Nuclear Medicine, Centre GF Leclerc, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Burroni","sequence":"additional","affiliation":[{"name":"16Department of Pathology, Universit\u00e9 de Paris Cit\u00e9, Centre de Recherche des Cordeliers UMRS U1138 et GH Paris Centre APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Damotte","sequence":"additional","affiliation":[{"name":"16Department of Pathology, Universit\u00e9 de Paris Cit\u00e9, Centre de Recherche des Cordeliers UMRS U1138 et GH Paris Centre APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Traverse-Glehen","sequence":"additional","affiliation":[{"name":"17Department of Pathology, Hopital Lyon Sud, Claude Bernard Lyon 1 University, Pierre Benite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2324-5660","authenticated-orcid":false,"given":"Philippe","family":"Quittet","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-8983","authenticated-orcid":false,"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[{"name":"19Department of Hematology, University Hospital F. Mitterrand and INSERM Unit\u00e9 Mixte de Recherche 1231, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2024031415212716800_bib1","first-page":"B4485","article-title":"On the aetiology of Hodgkin lymphoma","volume":"59","author":"Hjalgrim","year":"2012","journal-title":"Dan Med J"},{"issue":"1","key":"2024031415212716800_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/ejh.13090","article-title":"Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-a population-based study from Sweden","volume":"101","author":"Bj\u00f6rkholm","year":"2018","journal-title":"Eur J Haematol"},{"issue":"1","key":"2024031415212716800_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.15652","article-title":"The treatment of older Hodgkin lymphoma patients","volume":"184","author":"B\u00f6ll","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"2024031415212716800_bib4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A\u00a0retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2024031415212716800_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br J Haematol"},{"issue":"24","key":"2024031415212716800_bib6","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma","volume":"118","author":"B\u00f6ll","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2024031415212716800_bib7","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","article-title":"Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study","volume":"119","author":"Proctor","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2024031415212716800_bib8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024031415212716800_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/bloodadvances.2019000984","article-title":"Five-year results of the BEGEV salvage regimen in relapsed\/refractory classical Hodgkin lymphoma","volume":"4","author":"Santoro","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2024031415212716800_bib10","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/bjh.16499","article-title":"Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma","volume":"189","author":"LaCasce","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"2024031415212716800_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0899-9007(98)00171-3","article-title":"The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients","volume":"15","author":"Vellas","year":"1999","journal-title":"Nutrition"},{"issue":"15","key":"2024031415212716800_bib12","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2011.35.7442","article-title":"Predictors of early death risk in older patients\u00a0treated with first-line chemotherapy for cancer","volume":"30","author":"Soubeyran","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024031415212716800_bib13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024031415212716800_bib14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1532-5415.1968.tb02103.x","article-title":"Cumulative illness rating scale","volume":"16","author":"Linn","year":"1968","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"3","key":"2024031415212716800_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"2024031415212716800_bib16","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","article-title":"Studies of illness in the aged: the index of ADL\u2014a standardized measure of biological and psychosocial function","volume":"185","author":"Katz","year":"1963","journal-title":"JAMA"},{"issue":"8","key":"2024031415212716800_bib17","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"issue":"15 suppl","key":"2024031415212716800_bib18","article-title":"Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial","volume":"34","author":"Casasnovas","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024031415212716800_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"2024031415212716800_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"3","key":"2024031415212716800_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1745-3984.1970.tb00709.x","article-title":"The selection of variables in multiple regression analysis","volume":"7","author":"Halinski","year":"1970","journal-title":"J\u00a0Educ Meas"},{"issue":"4","key":"2024031415212716800_bib22","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"30","key":"2024031415212716800_bib23","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024031415212716800_bib24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"21","key":"2024031415212716800_bib25","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2024031415212716800_bib26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2307\/2530374","article-title":"The analysis of failure times in the presence of competing risks","volume":"34","author":"Prentice","year":"1978","journal-title":"Biometrics"},{"issue":"11","key":"2024031415212716800_bib27","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in\u00a0biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"issue":"5","key":"2024031415212716800_bib28","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged 60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2024031415212716800_bib29","article-title":"B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)","volume":"132","author":"B\u00f6ll","year":"2018","journal-title":"Blood"},{"issue":"18","key":"2024031415212716800_bib30","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/bloodadvances.2021004645","article-title":"Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma","volume":"5","author":"Orellana-Noia","year":"2021","journal-title":"Blood Adv"},{"issue":"22","key":"2024031415212716800_bib31","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1182\/bloodadvances.2022008258","article-title":"The outcome of older adults with classic Hodgkin lymphoma in British Columbia","volume":"6","author":"Cheng","year":"2022","journal-title":"Blood Adv"},{"key":"2024031415212716800_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.HS9.0000890896.83681.49","article-title":"AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients","volume":"6","author":"\u00d6vergaard","year":"2022","journal-title":"HemaSphere"},{"issue":"21","key":"2024031415212716800_bib33","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A\u00a0prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024031415212716800_bib34","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","article-title":"Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions","volume":"24","author":"Klimm","year":"2013","journal-title":"Ann Oncol"},{"issue":"13","key":"2024031415212716800_bib35","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2024031415212716800_bib36","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024031415212716800_bib37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/hon.2830","article-title":"Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland","volume":"39","author":"Moccia","year":"2021","journal-title":"Hematol Oncol"},{"issue":"4","key":"2024031415212716800_bib38","first-page":"1087","article-title":"Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen","volume":"20","author":"Weekes","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024031415212716800_bib39","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2023.01.014","article-title":"Characteristics and outcomes of older patients with classical Hodgkin lymphoma: an Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry study","volume":"23","author":"Goh","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2024031415212716800_bib40","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jha2.202","article-title":"Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged &gt;60 years","volume":"2","author":"Wahlin","year":"2021","journal-title":"EJHaem"},{"issue":"S2","key":"2024031415212716800_bib41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/hon.3163_107","article-title":"Phase 2 trial of Nivolumab plus Adriamycin, vinblastine, dacarbazine (N-AVD) as frontline therapy in older adults with Hodgkin lymphoma","volume":"41","author":"Torka","year":"2023","journal-title":"Hematol Oncol"},{"issue":"S2","key":"2024031415212716800_bib42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hon.3163_5","article-title":"Nivolumab (N)-AVD improves progression-free survival compared to brentuximab vedotin (BV)-AVD in advanced stage (AS) classical Hodgkin lymphoma (HL): results of SWOG S1826","volume":"41","author":"Herrera","year":"2023","journal-title":"Hematol Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/11\/983\/2218045\/blood_bld-2023-021564-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/11\/983\/2218045\/blood_bld-2023-021564-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T15:24:26Z","timestamp":1710429866000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/11\/983\/498770\/The-phase-2-LYSA-study-of-prednisone-vinblastine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,3,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021564","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]}}}